Chromosomal Microarray With Clinical Diagnostic Utility in Children With Developmental Delay or Intellectual Disability.
10.3343/alm.2018.38.5.473
- Author:
Jin Sook LEE
1
;
Hee HWANG
;
Soo Yeon KIM
;
Ki Joong KIM
;
Jin Sun CHOI
;
Mi Jung WOO
;
Young Min CHOI
;
Jong Kwan JUN
;
Byung Chan LIM
;
Jong Hee CHAE
Author Information
1. Department of Pediatrics, Department of Genome Medicine and Science, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
- Publication Type:Original Article
- Keywords:
Chromosomal microarray;
Copy number variation;
Developmental delay;
Intellectual disability;
Diagnostic utility
- MeSH:
Autistic Disorder;
Child*;
Cohort Studies;
Diagnosis;
Diagnostic Tests, Routine;
Genetic Counseling;
Humans;
Intellectual Disability*;
Korea;
Medical Records;
Microarray Analysis;
Parents;
Polymerase Chain Reaction;
Retrospective Studies;
Seoul;
Virulence
- From:Annals of Laboratory Medicine
2018;38(5):473-480
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Chromosomal microarray (CMA) testing is a first-tier test for patients with developmental delay, autism, or congenital anomalies. It increases diagnostic yield for patients with developmental delay or intellectual disability. In some countries, including Korea, CMA testing is not yet implemented in clinical practice. We assessed the diagnostic utility of CMA testing in a large cohort of patients with developmental delay or intellectual disability in Korea. METHODS: We conducted a genome-wide microarray analysis of 649 consecutive patients with developmental delay or intellectual disability at the Seoul National University Children's Hospital. Medical records were reviewed retrospectively. Pathogenicity of detected copy number variations (CNVs) was evaluated by referencing previous reports or parental testing using FISH or quantitative PCR. RESULTS: We found 110 patients to have pathogenic CNVs, which included 100 deletions and 31 duplications of 270 kb to 30 Mb. The diagnostic yield was 16.9%, demonstrating the diagnostic utility of CMA testing in clinic. Parental testing was performed in 66 patients, 86.4% of which carried de novo CNVs. In eight patients, pathogenic CNVs were inherited from healthy parents with a balanced translocation, and genetic counseling was provided to these families. We verified five rarely reported deletions on 2p21p16.3, 3p21.31, 10p11.22, 14q24.2, and 21q22.13. CONCLUSIONS: This study demonstrated the clinical utility of CMA testing in the genetic diagnosis of patients with developmental delay or intellectual disability. CMA testing should be included as a clinical diagnostic test for all children with developmental delay or intellectual disability.
